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The proficiency of cancer cells to repair DNA double-strand breaks (DSBs) by homologous recombination (HR) is
a key determinant in predicting response to targeted therapies such as PARP inhibitors. The RAD51 paralogs
work as multimeric complexes and act downstream of BRCA1 to facilitate HR. Numerous epidemiological studies
have linked RAD51 paralog mutations with hereditary cancer predisposition. Despite their substantial links to
cancer, RAD51 paralog HR function has remained elusive. Here we identify isoform 1 as the functional isoform
of RAD51D, whereas isoform 4 which has a large N-terminal deletion (including the Walker A motif), and
isoform 6 which includes an alternate exon in the N-terminus, are non-functional. To determine the importance
of this N-terminal region, we investigated the impact of cancer-associated mutations and SNPs in this variable
RAD51D N-terminal region using yeast-2-hybrid and yeast-3-hybrid assays to screen for altered protein-protein
interactions. We identified two cancer-associated mutations close to or within the Walker A motif (G96C and
G107 V, respectively) that independently disrupt RAD51D interaction with XRCC2. We validated our yeast in-
teraction data in human U2OS cells by co-immunoprecipitation and determined the impact of these mutations on
HR-proficiency using a sister chromatid recombination reporter assay in a RAD51D knock-out cell line. Our
investigation reveals that the interaction of RAD51D with XRCC2 is required for DSB repair. By characterizing
the impact of cancer-associated mutations on RAD51D interactions, we aim to develop predictive models for
therapeutic sensitivity and resistance in patients who harbor similar mutations in RAD51D.
1. Introduction
HR is a high-fidelity DSB repair mechanism that utilizes a homo-
logous template for repair [1]. Cells commit to HR by resecting the
broken DNA ends to yield a single-stranded DNA (ssDNA) overhang,
which becomes coated with Replication Protein A (RPA). RPA is then
exchanged for RAD51 recombinase to form a RAD51 nucleoprotein fi-
lament. RAD51 filaments perform the homology search and strand in-
vasion steps of HR [2]. RAD51 filament formation is aided by the
RAD51 paralogs, which structurally resemble RAD51 and if depleted,
impair HR [3].
There are six mammalian RAD51 paralogs including RAD51B,
RAD51C, RAD51D, XRCC2, XRCC3 and SWSAP1 [4,5]. These proteins
form distinct sub-complexes including BCDX2 (RAD51B, RAD51C,
RAD51D and XRCC2), CX3 (RAD51C and XRCC3) and the Shu complex
(SWSAP1 and SWS1) [4,6,7]. The RAD51 paralogs proteins have roles
in DNA integrity, including replication stress tolerance by promoting
DNA replication fork stability and restart, DNA DSB repair by pro-
moting RAD51 filament formation, and in the case of RAD51D, telo-
mere length maintenance [8–10]. The diverse requirements for these
proteins are also exemplified in yeast, where the RAD51 paralogs pro-
mote error-free damage tolerance of base-excision repair intermediates
following DNA alkylation as well as efficient DNA DSB repair [11].
Despite substantial evidence linking human RAD51 paralog mutations
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with breast and ovarian cancer, their function during DNA repair and
the impact of specific cancer-associated mutations remains largely un-
known [12–17].
Due to the early embryonic lethality observed in RAD51D knock-
outs in rodents, researchers used Rad51d-deficient Chinese hamster
ovary cell lines to determine the importance of RAD51D and found that
knock-outs exhibited an increased loss of genomic DNA resulting from
use of the alternative single-strand annealing pathway [18,19]. Like
RAD51, the RAD51D and XRCC2 contain canonical Walker A and
Walker B motifs, characteristic of proteins with ATPase activity
[20,21]. Despite this, whether or not ATPase activity of RAD51D is
required for DNA repair remains controversial. For example, two re-
ports suggest different requirements for the RAD51D Walker A motif for
its XRCC2 interaction and protein function [20,22].
Studies characterizing RAD51 paralog structure and function have
been plagued by poor protein solubility, low protein stability, and
profound sickness/lethality observed in knock-out model systems
[19,23–25]. In addition, it remains unknown which human RAD51D
isoform is responsible for mediating its HR functions. Here we de-
termine that RAD51D isoform 1 is the RAD51D isoform able to restore
HR in a RAD51D knock-out background. We then employed the pow-
erful yeast-2-hybrid (Y2H) and yeast-3-hybrid (Y3H) systems to study
the effect of cancer-associated mutations and population SNPs in
RAD51D on its interaction with XRCC2. We identified two glycine re-
sidues in close proximity to each other upstream and part of the Walker
A motif (G96 and G107, respectively) that are required for RAD51D
interaction with XRCC2. We validated our Y2H findings by co-im-
munoprecipitation in human U2OS cells. Importantly both the G96C
and G107 V RAD51D mutants alone or in combination exhibit reduced
HR, using a GFP-based sister chromatid recombination (SCR) reporter
assay [26]. Finally, we explored the possibility that the protein-protein
interactions of RAD51D, and ultimately its function, may be controlled
by post-translational modifications in this region.
2. Materials and methods
2.1. Tissue culture, cell lines and reagents
Human U2OS and U2OS SCR (Sister chromatid recombination) #18
Wild-Type (WT) [26] and RAD51D CRISPR Knock-out (Clone D4) cell
lines (both gifted from Mauro Modesti; Garcin et al., in preparation)
were cultured in DMEM supplemented with 10% (v/v) fetal bovine
serum (FBS), penicillin and streptomycin. Cells were transfected using
TransIT®-LT1 transfection reagent (Mirus Bio) diluted in OptiMEM®
serum free media and following the manufacturer’s instructions.
RAD51D cDNAs were expressed from mammalian expression plasmids
pCDNA3 FLAG-RAD51D isoform 1 (NM_002878.3) (gifted from Paul
Russell [27]), pCDNA3.1 3xFLAG-RAD51D isoform 4 (NM_133629.2)
and isoform 6 (NM_001142571.1) (supplied by Novoprolabs).
pCBASceI was a gift from Maria Jasin (Addgene plasmid # 26477) [28].
Mutations were introduced into the cDNA of RAD51D by site-directed
mutagenesis using Phusion polymerase master mix (M0531S, NEB) and
DpnI (R0176S, NEB). All mutations were verified by DNA sequencing
(Genewiz).
2.2. Sister chromatid recombination reporter assay
U2OS SCR #18 WT and RAD51D Knock-out (D4) cells were seeded
into a single well of a 6-well plate at 1× 105 and 2× 105 cells per well
respectively (due to slower growth of cells lacking RAD51D). Cells were
incubated for 24 h before co-transfection with an I-SceI expressing
plasmid and either an empty vector control or a vector expressing
FLAG-RAD51D using Mirus LT1 transfection reagent at a ratio of 1:2 of
plasmid DNA to transfection reagent. For co-transfections, a total of
5 μg of plasmid DNA was transfected per well in a 1:1 ratio of I-SceI to
Empty vector or FLAG-RAD51D). Transfection efficiency was assessed
by transfection of a separate sample of U2OS cells with eGFP. Following
transfection, cells were incubated for a further 48 h before trypsiniza-
tion and analysis by fluorescence activated cell sorting. For each assay,
50,000 events per experiment were analyzed in three experiments. To
account for variable transfection efficiency between experiments, re-
sults were normalized to one additional sample per experiment trans-
fected solely with pEGFP.
2.3. Yeast-2-hybrid and yeast-3-hybrid assays
For yeast-2-hybrid assays, a pGBD-RAD51D vector was used to ex-
press RAD51D C-terminally fused to the DNA-binding domain of GAL4
and a pGAD-XRCC2 vector was used to express XRCC2 C-terminally
fused to the GAL4-activation domain. PJ69-4 A cells were co-trans-
formed with the above plasmids and plated on synthetic complete
medium lacking leucine and tryptophan (SC-Leu—Trp—). Single-co-
lonies were selected and grown overnight. The following morning
cultures were diluted to 0.2 OD600 and cultured for a further 3 h (until
˜0.5 OD600) equal numbers of cells were spotted in 5 μl of culture
medium onto synthetic complete medium lacking leucine, tryptophan
and histidine (SC-Leu—Trp—His—; least stringent), with 3-amino-1,2,4-
triazole (SC-Leu—Trp—His— +3-AT; more stringent) or synthetic com-
plete medium lacking leucine, tryptophan, histidine and adenine (SC-
Leu—Trp—His—Ade—; most stringent). Plates were incubated for 48 h at
30 °C before taking images. All images were adjusted for brightness and
contrast identically using Adobe Photoshop.
For yeast 3-hybrid experiments, pGBD-RAD51D, pGAD-RAD51C
and pRS416-RAD51B were co-transformed into PJ69-4 A and trans-
formed onto synthetic complete medium lacking leucine, tryptophan
and uracil (SC-Leu—Trp—Ura—). As before, single-colonies were se-
lected and grown overnight. The following morning cultures were di-
luted to 0.2 OD600 and cultured for a further 3 h (until ˜0.5 OD600) equal
numbers of cells were spotted in 5 μl of culture medium on either SC-
Leu—Trp—Ura— His— medium; least stringent, SC-
Leu—Trp—Ura—His—+3-AT medium; more stringent or SC-
Leu—Trp—Ura— His—Ade— medium; most stringent. Medium with SC-
Leu—Trp—Ura— was used as a loading control. Plates were incubated
for 48 h at 30 °C before taking images. All images were adjusted for
brightness and contrast identically using Adobe Photoshop.
2.4. Co-immunoprecipitation
U2OS Cells were incubated for 24 h after transfection to express
FLAG-RAD51D and Myc-XRCC2. Cells were harvested by scraping into
cold phosphate-buffered saline (PBS) before lysis in lysis buffer sup-
plemented with protease inhibitors (A32965, Pierce™), phosphatase
inhibitors (A32957, Pierce™) and 2% (v/v) Benzonase (70746, Millipore
Sigma). Lysis buffer: 50mM Tris base, 100mM NaCl, 2 mM MgCl2, 10%
glycerol, 0.1% NP-40, 1mM DTT. Cell lysates were incubated for
30min on ice before clearing by centrifugation and incubation over-
night with c-Myc (9E10) agarose (sc-40 AC, Santa Cruz). The next day,
the agarose beads were washed four times with fresh lysis buffer before
addition of SDS-sample buffer and boiling for 5min. Input and elution
samples were run on SDS-PAGE and analyzed by Western blotting (as
described in 2.5). All images were adjusted for brightness and contrast
identically using Adobe Photoshop.
2.5. Western blot analyses
Samples harvested for Western blot analysis were run on 10% SDS-
PAGE gels. Proteins were transferred to PVDF membrane (Immobilon®-
FL, Millipore) before blocking for 1 h with Odyssey® blocking buffer
(927–50000, Licor®). Antibodies were diluted in a 1:1 ratio with (Tris
phosphate buffer) TBS and Odyssey® blocking buffer supplemented
with 0.2% Tween-20. Antibodies against FLAG-M2 (F3165, Sigma), c-
Myc (sc-789, Santa Cruz), RAD51D (sc-398819, Santa Cruz) and α-
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Tubulin (2144, Cell Signalling) were all used at a 1:1,000 dilution.
Antibodies against XRCC2 (TA327180, OriGene) was used at a 1:2,000
dilution. Secondary antibodies, IRDye®680RD anti-rabbit (926–68071,
Licor®) and IRDye®800CW (926–32210, Licor®), were used at 1:20,000.
Membranes were imaged using a Licor Odyssey® CLx imaging system.
3. Results and discussion
3.1. RAD51D splicing isoform 1, but not isoforms 4 or 6, are required for
repair of DSBs by HR
Upon the discovery of the murine and human RAD51D, it was noted
that several splicing isoforms exist [29]. Later investigation identified 7
RAD51D splice variants in both mice and humans. In humans, four of
the RAD51D isoforms are only found in brain tissue (RAD51DΔ3,5
RAD51DΔ5, RAD51DΔ4,5 and RAD51D+ int3Δ4,5) whereas the other
isoforms are differentially expressed in several tissues including brain,
kidney, mammary and lung tissues as well as in the testis, cervix,
prostate and spleen (RAD51DΔ3, RAD51DΔ3,4,5 and RAD51D+ int3
also referred to as transcript variants 1, 4 and 6, respectively) [30].
Investigation into the protein-protein interactions of the murine iso-
forms of RAD51D cells revealed that in mice, RAD51D isoform Δ7b is
proficient for interactions with both binding partners, RAD51C and
XRCC2, with a second murine isoform (RAD51D+ int3; synonymous
with human RAD51D splicing isoform 6) is only proficient for XRCC2
binding [30]. Interestingly, both isoforms fail to rescue sensitivity of
Rad51d-deficient cells to interstrand crosslinking agents [30]. We
cannot exclude the possibility that these splicing isoforms may have
altered protein stability, cellular localization or DNA-binding cap-
ability. It is also possible that expression of these alternate transcripts
may play a regulatory role in DNA repair by competing with full-length
RAD51D for interactions with its binding partners, RAD51C and
XRCC2.
To investigate the function of human RAD51D in response to DSBs,
we first aimed to determine which human RAD51D isoform is func-
tional. We identified three coding isoforms of human RAD51D, tran-
script variants 1, 4 and 6 from the nucleotide database provided by
NCBI [31]. Fig. 1A shows a schematic of the three isoforms tested.
Transcript isoform 1 contains both Walker A and B motifs and is pro-
posed to be the functional full-length protein at 328 amino acids in
length. Transcript isoform 4 is shorter at 216 amino acids in length,
lacking exons 3, 4 and 5 of exons 1–10 resulting in the loss of a portion
of the N-terminal region including the Walker A motif from the final
protein product. Transcript isoform 6 includes an alternate exon 3 re-
sulting in an extra region adjacent to the Walker A motif. This isoform is
longer than isoform 1 at 348 amino acids in length. Each of these iso-
forms can be N-terminally FLAG-tagged and are readily expressed in
U2OS RAD51D knock-out cell lines (Fig. 1B; Supplemental Fig. 1A). We
note that some degradation products are present in the cells expressing
exogenous RAD51D. It is well characterized that RAD51 paralogs do not
express efficiently without reciprocal binding partners to aid their
protein stability and solubility [6]. Despite this, we are able to observe
expression of each of these isoforms above endogenous RAD51D protein
levels.
To examine whether each isoform was DSB repair proficient, we
used a recombination reporter assay integrated into wild-type and
RAD51D knock-out U2OS cells (U2OS SCR clone 18; [26] Garcin et al.,
in preparation). This assay uses a GFP coding gene disrupted with an I-
SceI restriction site as well as an incomplete downstream GFP copy that
can be used for templated repair. If the DSB is repaired by HR, a
functional GFP gene is restored and can be analyzed by flow cytometry.
Analysis of GFP positive cells following co-transfection of I-SceI with
either RAD51D isoform 1, 4 or 6 in a RAD51D knock-out U2OS cell
reveals that only RAD51D isoform 1 restores HR following DSB in-
duction (Fig. 1C).
Both RAD51D splice variants, isoforms 4 and 6, only differ in their
N-terminus including and/or adjacent to the Walker A motif. We hy-
pothesized that mutations within this region may be critical for
RAD51D function. Previous studies defining the binding regions of
RAD51D with XRCC2 and RAD51C, demonstrated that the murine
Fig. 1. RAD51D splicing isoform 1, but not isoforms 4 or 6, rescues HR in
RAD51D knock-out U2OS cell lines.
(A) Schematic diagram of the three coding isoforms of RAD51D (isoforms 1, 4
and 6). Amino acid residue numbers of the Walker A (white box) and B (dark
grey box) motifs are shown in parenthesis. The extra coding region in isoform 6
is shown in black.
(B) U2OS wild-type or RAD51D knock-out cells were seeded on 35mm plates
24-hours prior to transfection with FLAG-RAD51D cDNA constructs. Following
transfection, cells were incubated for an additional 24-hours before lysis and
Western blot analysis for FLAG expression using α−Flag antibodies. α-Tubulin
was used as a loading control.
(C) Cells were seeded 24-hours prior to transfection as in B. Cells were co-
transfected with I-SceI and FLAG-RAD51D cDNAs or an empty vector control.
Cells were incubated for an additional 48-hours and then analyzed by flow
cytometry for green-fluorescence. The bar chart shows the average percentage
of GFP+ cells over three experiments. Error bars show one standard deviation
from the mean.
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RAD51D fragment (amino acids 4–77) is proficient for its XRCC2 in-
teraction but not with RAD51C. Gruver et al (2009) similarly found that
amino acids 54–77 are indispensable for murine RAD51D interaction
with XRCC2 [30]. In contrast, a RAD51D C-terminal fragment (amino
acids 77–328) is proficient for its RAD51C interaction, but not with
XRCC2 [32]. Taken together, it is possible that RAD51D isoforms 4 and
6 do not interact with XRCC2 due to the disruption or absence of this
region. Unfortunately, we are unable to test this hypothesis because
XRCC2 failed to efficiently express in cells co-transfected with RAD51D
isoforms 4 and 6, potentially indicating a RAD51 paralog complex
stability impairment. Therefore, it is possible that specific RAD51D
point mutations in this region could be used to disrupt the interaction of
RAD51D with its binding partners, XRCC2 and RAD51C.
3.2. Identification of cancer-associated RAD51D mutations, G96C and
G107V, impair its interaction with XRCC2 and RAD51C in a yeast-2-hybrid
and yeast-3-hybrid system, respectively
Having established that RAD51D transcript isoform 1 is the func-
tional isoform required for DSB repair, we next examined RAD51D’s
protein interactions with the other RAD51 paralogs using a Y2H ap-
proach. Similar to what has been reported [33], RAD51 paralog pro-
tein-protein interactions can be readily observed by Y2H (Fig. 2A and
B). Previous work demonstrated that RAD51D, as a member of the
BCDX2 complex, directly interacts with both XRCC2 and RAD51C
[6,34]. Each of these interactions can be readily assayed in the Y2H
(XRCC2) or Y3H (RAD51C) system (Fig. 2). Note that RAD51D inter-
action with RAD51C is examined using a Y3H approach because
RAD51B helps stabilize RAD51C expression (Fig. 2E; [22]). We find
that RAD51D exhibits the strongest Y2H interaction with XRCC2 and
does not exhibit a Y2H interaction with XRCC3, RAD51B, SWSAP1, or
SWS1 (Fig. 2A). Therefore, Y2H and Y3H assays can be used to quickly
screen RAD51D mutations to determine whether any of the observed
protein-protein interactions are affected.
We next wanted to screen cancer-associated mutations and germline
SNPs in the N-terminal half of RAD51D for altered protein-protein in-
teractions. To do this, we used the publicly available COSMIC and
EXOME databases [Table 1; schematic of mutations shown in red
(cancer-associated) and green (SNPs) in Fig. 2C]. Due to the high
number of cancer-associated mutations, several mutations in the N-
terminus of RAD51D were selected using the PolyPhen-2 server
(Table 2). PolyPhen-2 predicts the likelihood of an amino acid sub-
stitution mutation having an impact on the structure and/or function of
a protein based on the gene structural and evolutionary conservation
[35]. Based on this information, the PolyPhen-2 generates a score be-
tween (0 and 1) with a score of 1 being an amino acid substitution most
likely to be damaging to the proteins function. We introduced sub-
stitution mutations into the cDNA of RAD51D that were predicted to be
‘possibly damaging’ or ‘probably damaging’ prior to screening for al-
tered Y2H interactions. The use of ‘possibly damaging’ and ‘probably
damaging’ classifications is used to specify the confidence in the pre-
diction based on the false positive rate thresholds set by the server.
Of the seven cancer-associated mutations and SNPs in RAD51D
screened, only the RAD51D-G107 V mutation exhibited a strongly im-
paired Y2H interaction with XRCC2 (Fig. 2D). RAD51D-D90 G and
RAD51D-G96C exhibited modest XRCC2 Y2H impairment upon the
higher stringency plates (Fig. 2D; more and most stringent plates). To
further investigate this, we introduced the RAD51D-G107 V and the
nearby G96C mutation into the Y3H system to test their interaction
with RAD51C. We find that RAD51D- G107 V exhibits impaired inter-
action with both RAD51C and XRCC2. Note that the RAD51D-G96C
mutant exhibited a modest Y3H impairment upon the higher stringency
plates (Fig. 2E). Together these results suggest that G96 and G107 may
be important residues in RAD51D for its protein interactions. (caption on next page)
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3.3. Cancer-associated RAD51D mutations, G96C, G107V and the double-
mutant G96C/G107V, exhibit impaired XRCC2 interaction and HR-
proficiency in human cells
Following identification of RAD51D cancer-associated mutations
that disrupt its XRCC2 interaction in yeast, we next aimed to validate
these findings in mammalian cells. To do this, we first determined that
the mutant RAD51D proteins (RAD51D-G96C, RAD51D-G107 V, and
RAD51D-G96C/G107 V) are stably expressed in human U2OS cells
following transfection (Fig. 3A). Next, we performed co-im-
munoprecipitation experiments by co-transfecting either wild-type
FLAG-RAD51D or mutant FLAG-RAD51D with Myc-XRCC2. In contrast
to wild-type RAD51D, both RAD51D-G96C and RAD51D-G107 V mu-
tants exhibit an impaired XRCC2 interaction (Fig. 3B). Note that the
Y2H system enables examination of direct protein interactions, whereas
in human cells, these interactions may be stabilized by other binding
proteins. This likely accounts for the partial deficiency observed in the
RAD51D-XRCC2 interaction by co-immunoprecipitation. To fully in-
vestigate the potential impact of these mutants in human cells, we also
generated a double RAD51D mutant (RAD51D-G96C/G107 V). The
RAD51D double-mutant further decreased the ability of RAD51D to co-
immunoprecipitate with XRCC2, indicating that both of these residues
independently contribute to the RAD51D-XRCC2 protein interaction.
Since we identified important residues in RAD51D for its XRCC2
interaction, we next examined whether impairing RAD51D’s interaction
with XRCC2 would result in impaired HR. To test this, we com-
plemented a RAD51D knockout cell line containing a recombinational
reporter assay with either RAD51D wild-type or the G96C, G107 V or
the double-mutant (Fig. 3C). We find that both single-mutations failed
to fully rescue HR in the RAD51D knock-out cell lines, producing a
˜65% decrease in HR events (Fig. 3C). This HR defect was further
compounded when cells were transfected with the RAD51D double-
G96C/G107V-mutant (Fig. 3C). These results suggest that the interac-
tion between RAD51D with its binding partner XRCC2 is important for
RAD51D’s HR function.
Following the identification of mutants adjacent to the RAD51D
Walker A motif, we sought to clarify whether or not the Walker A is
dispensable for DSB repair by HR. Despite varied reports regarding a
functional requirement of the Walker A motif in tolerating MMC-in-
duced DNA damage [20,22], we find that the expression of RAD51D
containing point mutations, K113A and K113R, fails to fully restore HR
proficiency in RAD51D knock-out U2OS cells (Fig. 3D). This suggests
that although K113A/R mutants do not disrupt the RAD51D-XRCC2
interaction [20,22], there is a partial requirement for the RAD51D
Walker A K113 residue, at least in the context of DSB repair by HR.
3.4. Mutation of N-terminal residues that are potentially post-
translationally modified do not affect RAD51D protein-protein interactions
in yeast or HR-proficiency in human cells
RAD51 paralog function is regulated through protein-protein in-
teractions and also through post-translational modifications. For ex-
ample, XRCC3 is phosphorylated on Ser225 by ATR-kinase and this
phosphorylation event is critical for RAD51 loading [41]. More re-
cently, RAD51D protein levels were shown to be ubiquitin regulated by
the E3-ubiquitin ligase, RNF138 [42,43]. Having identified two
Fig. 2. Identification of cancer-associated mutations, G96V and G107V, in
RAD51D that impair its interaction with XRCC2 and RAD51C.
(A) Yeast 2-hybrid analysis showing the interactions of each of the RAD51
paralogs (and SWS1, a SWIM-domain containing protein) with each other. The
PJ694a yeast strain was transformed with a plasmid where RAD51, the RAD51
paralogs (RAD51B, RAD51C RAD51D, SWSAP1, XRCC2, and XRCC3) and SWS1
were cloned into a plasmid that expresses the GAL4 DNA activating (pGAD) and
GAL4 DNA binding (pGBD) domains. A yeast-2-hybrid interaction was assayed
by platting the yeast on SC-Leu—Trp—His— and compared to the empty pGAD
or pGBD plasmids, which were used as negative controls. Note that XRCC3
analysis had to be performed on a separate plate because of the plate size and
that, consistent with the yeast Rad51 paralogs, human RAD51 Y2H interactions
with the RAD51 paralogs are only observed when RAD51 is expressed in the
pGAD vector [57].
(B) Diagram representing the protein-protein interaction between the RAD51
paralog subcomplexes shown in the part A. BCDX2 is composed of RAD51B
(light green), RAD51C (grey), RAD51D (blue), and XRCC2 (yellow). The CX3
complex is composed of RAD51C (grey) and XRCC3 (orange) and the Shu
complex composed of SWSAP1 (light blue) and SWS1 (green).
(C) Schematic diagram showing RAD51D Walker motifs (white and dark grey
boxes) as well as SNPs (green), cancer-associated mutations (red) and poten-
tially post-translationally modified residues (blue) analyzed.
(D) Yeast-2-hybrid analysis of SNPs and cancer-associated mutations in
RAD51D on its interaction with XRCC2. The PJ694a yeast strain was trans-
formed with a plasmid where RAD51D or the indicated RAD51D mutation was
fused to the GAL4-DNA binding domain [BD; pGBD-RAD51D (WT)] and a
plasmid where XRCC2 was fused to the GAL4-DNA activating domain (AD;
pGAD-XRCC2). A yeast-2-hybrid interaction was assayed by platting the yeast
on SC-Leu—Trp—His— (least stringent), SC-Leu—Trp—His—+3AT (more strin-
gent), or SC-Leu—Trp—His—Ade— (most stringent) and compared to the loading
control (SC-Leu—Trp—). Empty AD (pGAD; Empty) plasmid was used as a ne-
gative control.
(E) Yeast-3-hybrid analysis of RAD51D-G96C and/or -G107 V mutations with
XRCC2 and RAD51C. The PJ694a yeast strain was transformed with three
plasmids; 1) a plasmid where RAD51D (or the indicated mutant) was fused to
the GAL4-DNA binding domain [BD; pGBD-RAD51D (WT)], 2) a plasmid where
either XRCC2 or RAD51C was fused to the GAL4-DNA activating domain (AD;
pGAD-XRCC2, pGAD-RAD51C), and 3) a plasmid that constitutively expressed
RAD51B (pRS416-RAD51B). Note that a plasmid containing RAD51B was used
to help stabilize RAD51C expression. A yeast-3-hybrid interaction between
RAD51D with XRCC2 or RAD51C was assayed by platting the yeast on SC-
Leu—Trp—Ura—His— (least stringent), SC-Leu—Trp—Ura—His—+3AT (more
stringent), or SC-Leu—Trp—Ura—His—Ade— (most stringent) and compared to
the loading control SC-Leu—Trp—Ura— (Loading). Empty pGBD (BD Empty) and
pGAD (AD Empty) plasmids were used as negative controls.
Table 1
RAD51D mutations identified in EXOME and COSMIC databases. Table shows
which mutations are germline SNPs (green) and which are somatic cancer-as-
sociated mutations (red). Table details the tissue in which the mutation was
originally identified.
Mutation Tissue origin Database Somatic vs
Germline
References
Not Applicable EXOME Germline [36]
Not Applicable EXOME Germline [36]
Not Applicable EXOME Germline [36]
Not Applicable EXOME Germline [36]
Ovary N/A Germline [37]
Lung (Small Cell
Carcinoma)
COSMIC Somatic [38,39]
Lung (Squamous Cell
Carcinoma)
COSMIC Somatic [40]
Table 2
RAD51D PolyPhen-2 analysis. RAD51D isoform 1 was entered in FASTA format
along with the amino acid substitution and position information. Mutation
scores were generated along with a prediction of whether the mutation would
be benign, possibly or probably damaging. Mutations analyzed were selected on
the basis of the mutation being ‘possibly damaging’ or ‘probably damaging’.
Mutation Score Prediction
0.936 Possibly Damaging
0.933 Possibly Damaging
0.9 Possibly Damaging
0.735 Possibly Damaging
0.999 Probably Damaging
1 Probably Damaging
0.999 Probably Damaging
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RAD51D cancer-associated mutations in the N-terminus that influence
its protein interactions and HR function, we wanted to explore the
possibility that RAD51D might also be regulated through post-
translational modifications in this region. To determine the potential
role of RAD51D post-translational modifications, we collated mass
spectrometry data on modified peptides from the publicly available
database, PhosphoSitePlus (Table 3) [44]. We identified four residues
in RAD51D that were modified by either phosphorylation or, in the case
of lysine, acetylation (Tyr98, Thr99, Thr236 and K261R; Fig. 2C). Re-
sidues Tyr98 and Thr99 were of particular interest as they resided be-
tween the Gly96 and Gly107 residues needed for RAD51D protein-
protein interactions and HR (Fig. 2C).
We then tested whether mutation of these residues disrupted the
interaction of RAD51D with XRCC2 or RAD51C using the Y2H and Y3H
assays, respectively. Residues were tested by either substituting an
unmodifiable amino acid residue (mutation to alanine) or a phospho-
mimetic residue (mutation to glutamate). Secondly in the case of tyr-
osine, as there is not a suitable substitution to introduce a negative
charge onto the benzene ring, only the unmodifiable substitution was
introduced (mutation to Alanine or Phenylalanine in the double-mu-
tant). Finally, the acetylated lysine was substituted with arginine,
which cannot be modified. Additionally, as two of the residues are
adjacent to each other (Tyr98 and Thr99), a double-mutant was gen-
erated to account for any potential redundancy between these phos-
phorylation sites. We find that none of the substitution mutations in
Fig. 3. RAD51D-G96C, -G107 V and the double -G96C/G107 V mutant exhibit
impaired XRCC2 interaction and HR in human U2OS cells.
(A) U2OS wild-type or RAD51D knock-out cells were seeded on 35mm plates
24-hours prior to transfection with FLAG-RAD51D mutant cDNA constructs.
Following transfection, cells were incubated for a further 24-hours before lysis
and Western blot analysis for FLAG expression using αFLAG antibodies. α-
Tubulin was used as a loading control.
(B) Co-immunoprecipitation of Myc-XRCC2 with FLAG-RAD51D-G96C, G107 V
and the double-mutant from human U2OS cells. U2OS cells were seeded on
100mm plates 24-hours prior to transfection with FLAG-RAD51D wild-type or
mutant cDNA constructs (NT=not transfected). Following transfection, cells
were incubated for an additional 24-hours before lysis. Lysates were incubated
overnight at 4 °C with α-Myc agarose beads. The next day, the agarose beads
were washed and the co-immunoprecipitates were eluted using SDS-sample
buffer. Samples were analyzed by Western blotting for α-FLAG (co-im-
munoprecipitation) and α-Myc (immunoprecipitation). Western blot band
densitometry was calculated using Image Studio software, co-im-
munoprecipitation FLAG-band intensity (Co-IP Quantification) was normalized
to immunoprecipitation (IP: Myc) and to input FLAG expression to account for
transfection efficiency and any variability in the immunoprecipitation.
*Signifies the bands produced by cross-reactivity of the secondary antibody
with IgG light-chain of the Myc antibody used for immunoprecipitation.
(C) U2OS wild-type or RAD51D knock-out cells were seeded on 35mm plates
24-hours prior to transfection with the indicated FLAG-RAD51D cDNA mutant
constructs. Cells were co-transfected with either I-SceI and FLAG-RAD51D
cDNAs or I-SceI and an empty vector control. Cells were incubated for an ad-
ditional 48-hours and analyzed by flow cytometry for green-fluorescence. The
bar chart shows the average percentage of GFP+ cells over three experiments.
Error bars show one standard deviation from the mean.
(D) U2OS wild-type or RAD51D knock-out cells were seeded and transfected as
in 3C (including K113 A and K113R; Walker A motif mutants). Cells were in-
cubated for an additional 48-hours and analyzed by flow cytometry for green-
fluorescence. The bar chart shows the average percentage of GFP+ cells over
three experiments. Error bars show one standard deviation from the mean.
Table 3
RAD51D PTMs identified in the PhosphoSitePlus database.
Residue Modification Substitutions References
Y98 Phosphorylation Mutation to Alanine (A) [45]
T99 Phosphorylation Mutation to Alanine (A) and Glutamate
(E)
[45]
T236 Phosphorylation Mutation to Alanine (A) and Glutamate
(E)
[44]
K261 Acetylation Mutation to Arginine (R) [46]
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RAD51D disrupted its Y2H or Y3H interaction with either XRCC2 or
RAD51C (Fig. 4A and B).
Although we find that substitution mutations that prevent or mimic
protein modifications do not significantly alter any protein-protein in-
teractions by Y2H or Y3H, it is possible that modification of these re-
sidues may be important for RAD51D HR function. To test whether
substitution of residues Tyr98 and Thr99 impair RAD51D DNA repair
function, we introduced RAD51D-Y98 and T99 mutations into RAD51D
knock-out cells and determined whether they were expressed and HR
proficient using a GFP-based sister chromatid recombination reporter
assay (Fig. 4C and D). Expression of both Y98A and T99A/E along with
the double-mutant (T99F/T99E) as well as T236A/E and K261R suc-
cessfully restored HR in RAD51D knock-out cells (Fig. 4C; Supplemental
Fig. 1B). Therefore, modification of RAD51D residues, Y98, T99, T236
or K261 do not significantly alter RAD51D HR function.
Although we do not observe any HR-repair defects upon mutation of
the post-translational modification sites in RAD51D, it is possible that
these residues may be important for RAD51D function in other contexts
such as replication-associated DNA damage. Further assays designed to
test the functionality of RAD51D in response to different types of DNA
damage or in response to different genotoxic agents will be necessary to
test this.
3.5. Concluding remarks
Here we identified isoform 1 of RAD51D to be the functional
RAD51D isoform, and we identified two cancer-associated residues in
the N-terminus (G96 and G107) that are independently important for
RAD51D protein interactions and HR function. Both of these mutations
are close to the Walker A motif, with G107V being the first glycine
residue within the conserved Walker A motif. Previous studies have
presented contradictory requirements for the Walker A and Walker B
Fig. 4. Mutations of residues in RAD51D that are potentially post-translation-
ally modified do not affect the interaction of RAD51D with RAD51C or XRCC2
and do not affect HR-proficiency.
(A) Yeast 2-hybrid analysis of potential post-translationally modified residues in
RAD51D on its interaction with XRCC2. The PJ694a yeast strain was trans-
formed with a plasmid where RAD51D or the indicated RAD51D mutation was
fused to the GAL4-DNA binding domain [BD; pGBD-RAD51D (WT)] and a
plasmid where XRCC2 was fused to the GAL4-DNA activating domain (AD;
pGAD-XRCC2). A yeast-2-hybrid interaction was assayed by platting the yeast
on SC-Leu—Trp—His— (least stringent), SC-Leu—Trp—His—+3AT (more strin-
gent), or SC-Leu—Trp—His—Ade—(most stringent) and compared to the loading
control (SC-Leu—Trp—). Empty AD (pGAD; Empty) plasmid was used as a ne-
gative control.
(B) Yeast 3-hybrid analysis of potential post-translationally modified residues in
RAD51D on its interaction with XRCC2 and RAD51C. The PJ694a yeast strain was
transformed with three plasmids; 1) a plasmid where RAD51D (or the indicated
mutant) was fused to the GAL4-DNA binding domain [BD; pGBD-RAD51D (WT)],
2) a plasmid where either XRCC2 or RAD51C was fused to the GAL4-DNA acti-
vating domain (AD; pGAD-XRCC2, pGAD-RAD51C), and 3) a plasmid that con-
stitutively expressed RAD51B (pRS416-RAD51B). Note that a plasmid containing
RAD51B was used to help stabilize RAD51C expression. A yeast-3-hybrid inter-
action between RAD51D with XRCC2 or RAD51C was assayed by platting the yeast
on SC-Leu—Trp—Ura—His— (least stringent), SC-Leu—Trp—Ura—His—+3AT (more
stringent), or SC-Leu—Trp—Ura—His—Ade—(most stringent) and compared to the
loading control SC-Leu—Trp—Ura— (Loading). Empty pGBD (BD Empty) and pGAD
(AD Empty) plasmids were used as negative controls.
(C) U2OS wild-type (WT) or RAD51D knock-out cells were seeded on 35mm plates
24-hours prior to transfection with FLAG-RAD51D cDNA mutant constructs. Cells
were co-transfected with either I-SceI and FLAG-RAD51D cDNAs containing re-
sidue substitutions or I-SceI and an empty vector control. Cells were incubated for
an additional 48-hours after which, cells were analyzed by flow cytometry for
green-fluorescence. The bar chart shows the average percentage of GFP+cells
over three experiments. Error bars show one standard deviation from the mean.
(D) U2OS wild-type (WT) or RAD51D knock-out cells were seeded on 35mm plates
24-hours prior to transfection with FLAG-RAD51D cDNA containing residue sub-
stitutions. Following transfection, cells were incubated for an additional 24-hours
before lysis and Western blot analysis for RAD51D expression was done using
αFLAG and αRAD51D antibodies. α-Tubulin was used as a loading control. The
star indicates a non-specific band.
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motifs for RAD51D function in response to DNA damage, specifically in
tolerating DNA interstrand crosslinks. Gruver et al (2005) show that the
RAD51D Walker A mutations K113A and K113R fail to restore re-
sistance to DNA crosslinking agent, Mitomycin-C (MMC), in Rad51d-
deficient mouse embryonic fibroblasts when compared to wild-type
RAD51D [20]. Furthermore, using the Y2H system, they demonstrate
that RAD51D-K113A and K113R mutations primarily impair RAD51D’s
interaction with RAD51C, while its interaction with XRCC2 was largely
unaffected. In contrast, Wiese et al (2006) demonstrated that the same
RAD51D mutations, K113A and K113R, maintain their interaction with
both RAD51C and XRCC2 and that these mutants do indeed restore
MMC resistance in Rad51d-knock-out CHO cells [22]. In addition, they
showed that it is actually the RAD51D Walker B motif that is critical for
its RAD51C and XRCC2 interactions and MMC resistance. By expressing
RAD51D cDNAs with the same mutations (K113A/R) in RAD51D knock-
out cell lines, we observe a partial requirement for the Walker A K113
residue for the repair of a DSB by HR. Although we cannot discount any
cell line or organism-specific differences between these studies, our
data supports the conclusion that conservation of the Walker A motif of
RAD51D is required for both its protein-protein interactions with both
RAD51C and XRCC2 as well as its HR function.
RAD51D is now included on the comprehensive breast and ovarian
cancer screening panels [47,48]. However, the vast majority of muta-
tions identified remain variants of unknown significance. This has im-
portant clinical ramifications for the development of precision medicine
approaches for HR-deficient tumors. Most notably, the use of poly-ADP-
ribose polymerase inhibitors (PARPi) has revolutionized breast and
ovarian cancer treatment [49–51]. PARPi exploit a synthetic lethality
created by the loss of BRCA1 and BRCA2 mutations commonly observed
in breast and ovarian cancer predisposition [52,53]. BRCA1 and BRCA2
loss results in HR deficiency [54,55], and this opens the possibility that
other HR-deficient tumors will similarly respond to PARPi therapy.
Therefore, the ability of cancer cells to repair DSBs by HR is key in
predicting the sensitivity and response to PARPi. Previously, BRCA1/2
mutations were utilized to indicate HR-proficiency, however BRCA
mutation alone does not accurately predict PARPi sensitivity in clinical
trials [56]. By understanding which regions of RAD51D are important
for its protein interactions and ultimately HR function, we will be better
able to predict who might be a good candidate for PARPi therapy.
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